Tocilizumab for Chronic Graft-versus-Host Disease Treatment

Summary

This phase II trial studies how well tocilizumab works in treating chronic graft-versus-host disease (GVHD) in patients that have not responded to treatment after at least two prior therapies. Tocilizumab blocks a protein that stimulates the body's immune system. By blocking this protein, the investigators may reduce the symptoms of chronic GVHD.

Timeline

Start

2016-02

Primary completion

2019-08

Completion

—

Outcome

Outcome not reported

Stopped (Business): “Study never opened due to lack of funds.”

Drugs

Indications